Low Impact of Clonal Hematopoiesis on the Determination of RAS Mutations by Cell-Free DNA Testing in Routine Clinical Diagnostics
暂无分享,去创建一个
D. Frezzetti | N. Normanno | A. De Luca | M. Maiello | G. Nasti | A. Morabito | L. Forgione | C. Roma | M. Lambiase | R. Esposito Abate | A. Sacco | S. Dotolo
[1] J. Lindberg,et al. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. , 2022, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] J. Reis-Filho,et al. Delivering precision oncology to patients with cancer , 2022, Nature Medicine.
[3] N. Kraut,et al. Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants , 2022, Cancer discovery.
[4] Myung Ah Lee,et al. Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial. , 2021, The Lancet. Oncology.
[5] A. Biankin,et al. Cancer Biomarkers in the era of precision oncology: Addressing the needs of patients and health systems. , 2021, Seminars in cancer biology.
[6] P. Jänne,et al. Abstract LB002: Mechanisms of acquired resistance to KRAS G12C inhibition in cancer , 2021, Experimental and Molecular Therapeutics.
[7] V. Fedele,et al. Targeting KRAS: The Elephant in the Room of Epithelial Cancers , 2021, Frontiers in Oncology.
[8] A. Chakraborty. KRASG12C inhibitor: combing for combination. , 2020, Biochemical Society transactions.
[9] R. Yamashita,et al. Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies , 2020, Nature Medicine.
[10] P. Ascierto,et al. Circulating Tumor DNA Testing Opens New Perspectives in Melanoma Management , 2020, Cancers.
[11] D. Steensma,et al. Implications of Clonal Hematopoiesis for Precision Oncology. , 2020, JCO precision oncology.
[12] Hiu Ting Chan,et al. Clinical significance of clonal hematopoiesis in the interpretation of blood liquid biopsy , 2020, Molecular oncology.
[13] S. Mortimer,et al. Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non–small cell lung cancer: Analysis of over 8000 cases , 2020, Cancer.
[14] T. Druley,et al. The evolutionary dynamics and fitness landscape of clonal hematopoiesis , 2020, Science.
[15] C. Curtis. Quantifying mutations in healthy blood , 2020, Science.
[16] N. Normanno,et al. Targeted sequencing analysis of cell-free DNA from metastatic non-small-cell lung cancer patients: clinical and biological implications , 2020, Translational lung cancer research.
[17] N. Chen,et al. Discovery of a covalent inhibitor of KRASG12C (AMG 510) for the treatment of solid tumors. , 2019, Journal of medicinal chemistry.
[18] David R. Jones,et al. High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants , 2019, Nature Medicine.
[19] N. Rosenfeld,et al. Real-World Utility of an Amplicon-Based Next-Generation Sequencing Liquid Biopsy for Broad Molecular Profiling in Patients With Advanced Non–Small-Cell Lung Cancer , 2019, JCO precision oncology.
[20] G. Botti,et al. The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients , 2019, Cancers.
[21] M. Ye,et al. Biological background of the genomic variations of cf-DNA in healthy individuals , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[22] N. Normanno,et al. The role of circulating free DNA in the management of NSCLC , 2018, Expert review of anticancer therapy.
[23] Sharyn I. Katz,et al. Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non–Small Cell Lung Cancer , 2019, JAMA oncology.
[24] M. Speicher,et al. Current and future perspectives of liquid biopsies in genomics-driven oncology , 2018, Nature Reviews Genetics.
[25] N. Normanno,et al. The liquid biopsy in the management of colorectal cancer patients: Current applications and future scenarios. , 2018, Cancer treatment reviews.
[26] B. Chabner,et al. Application of Cell-free DNA Analysis to Cancer Treatment. , 2018, The New England journal of medicine.
[27] C. Paweletz,et al. False-Positive Plasma Genotyping Due to Clonal Hematopoiesis , 2018, Clinical Cancer Research.
[28] S. Ikeda,et al. Genomic Alterations in Circulating Tumor DNA from Diverse Cancer Patients Identified by Next-Generation Sequencing. , 2017, Cancer research.
[29] Jacqueline A. Hall,et al. Review of the implementation of plasma ctDNA testing on behalf of IQN Path ASBL: a perspective from an EQA providers’ survey , 2017, Virchows Archiv.
[30] James D. Brenton,et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA , 2017, Nature Reviews Cancer.
[31] T. Druley,et al. Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults , 2016, Nature Communications.
[32] G. Botti,et al. Limits and potential of targeted sequencing analysis of liquid biopsy in patients with lung and colon carcinoma , 2016, Oncotarget.